High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group

Introduction. Osteosarcoma relapse has a poor prognosis, with less than 25% survival at 5 years. We describe the experience of the French Society of Paediatric Oncology (SFCE) with high dose (HD) thiotepa and autologous stem cell transplantation (ASCT) in 45 children with relapsed osteosarcoma. Pati...

詳細記述

保存先:
書誌詳細
主要な著者: Marec-Berard, Perrine, Segura-Ferlay, Céline, Tabone, Marie-Dominique, Pacquement, Helene, Lervat, Cyril, Gentet, Jean-Claude, Schmitt, Claudine, Gaspar, Nathalie, Brugières, Laurence
フォーマット: Artigo
言語:Inglês
出版事項: Hindawi Publishing Corporation 2014
主題:
Clinical Study
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3941142/
https://ncbi.nlm.nih.gov/pubmed/24672280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/475067
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料